Wedbush Forecasts Biogen’s Q1 Earnings (NASDAQ:BIIB)

Biogen Inc. (NASDAQ:BIIB) – Wedbush dropped their Q1 2025 earnings estimates for Biogen in a research report issued to clients and investors on Thursday, February 13th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings of $3.82 per share for the quarter, down from their prior estimate of $3.97. The consensus estimate for Biogen’s current full-year earnings is $16.42 per share. Wedbush also issued estimates for Biogen’s FY2027 earnings at $17.85 EPS.

A number of other research firms have also recently weighed in on BIIB. Royal Bank of Canada decreased their target price on shares of Biogen from $231.00 to $225.00 and set an “outperform” rating on the stock in a research note on Thursday, February 13th. TD Cowen decreased their target price on shares of Biogen from $300.00 to $275.00 and set a “buy” rating on the stock in a research note on Thursday, October 31st. Citigroup decreased their target price on shares of Biogen from $160.00 to $145.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. Wolfe Research assumed coverage on shares of Biogen in a research note on Friday, November 15th. They set a “peer perform” rating on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Biogen in a research note on Thursday, February 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $211.85.

Biogen Stock Performance

Shares of NASDAQ:BIIB opened at $136.57 on Monday. The company’s 50 day simple moving average is $146.52 and its 200 day simple moving average is $172.19. The stock has a market capitalization of $19.90 billion, a price-to-earnings ratio of 12.34, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08. Biogen has a 1 year low of $128.51 and a 1 year high of $238.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently made changes to their positions in the business. Inspire Trust Co. N.A. raised its holdings in shares of Biogen by 58.5% in the 3rd quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company’s stock worth $2,113,000 after acquiring an additional 4,025 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Biogen by 0.3% in the 4th quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company’s stock worth $6,646,000 after purchasing an additional 111 shares in the last quarter. Centre Asset Management LLC grew its position in Biogen by 7.7% in the 4th quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company’s stock worth $7,880,000 after purchasing an additional 3,698 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Biogen by 1.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 913,029 shares of the biotechnology company’s stock worth $176,982,000 after purchasing an additional 12,319 shares in the last quarter. Finally, Principal Financial Group Inc. grew its position in Biogen by 3.2% in the 3rd quarter. Principal Financial Group Inc. now owns 168,631 shares of the biotechnology company’s stock worth $32,687,000 after purchasing an additional 5,270 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.